Cellular interaction and cytotoxicity of the Iowa mutation of apolipoprotein A-I (ApoA-IIowa) amyloid mediated by sulfate moieties of heparan sulfate

Journal of Biological Chemistry

Volumn 290, Issue 40, 2015, Pages 24210-24221

  Kuwabara, Kaori ^a   Nishitsuji, Kazuchika ^a   Uchimura, Kenji ^b   Hung, Shang Cheng ^c   Mizuguchi, Makoto ^a   Nakajima, Hiroyuki ^a   Mikawa, Shiho ^a   Kobayashi, Norihiro ^d   Saito, Hiroyuki ^a   Sakashita, Naomi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANES; CELLS; CYTOLOGY; CYTOTOXICITY; ENZYME INHIBITION; IODINE; LIPOPROTEINS; SULFUR COMPOUNDS;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-I (APOA-I); CELLULAR INTERACTION; CHEMICAL REAGENTS; ENZYMATIC REMODELING; EXTRACELLULAR MATRICES; GLYCOSAMINOGLYCANS; SULFATED GLYCOSAMINOGLYCANS;

GLYCOPROTEINS;

AMYLOID; APOLIPOPROTEIN A1; ENDOGLUCOSAMINE 6 SULFATASE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; REAGENT; SULFATASE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; APOA1 PROTEIN, HUMAN; GLYCOSIDE; HEPARIN; PROTEIN BINDING; SULFATE; SULFUR; XYLOSIDES;

ANIMAL CELL; ARTICLE; CELL INTERACTION; CELL LINE; CELL SURFACE; CHO CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; FEMALE; MUTATION; NONHUMAN; PGSD 677 CELL; PRIORITY JOURNAL; PROTEIN TRANSPORT; SULFATION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CELL MEMBRANE; CHEMISTRY; CRICETULUS; FAMILIAL AMYLOID POLYNEUROPATHY; FLUORESCENCE MICROSCOPY; GENETICS; HAMSTER; HUMAN; LYSOSOME; MOUSE; PIG; PROTEIN TERTIARY STRUCTURE;

AMYLOID; AMYLOID BETA-PEPTIDES; AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOGENIC PROTEINS; ANIMALS; APOLIPOPROTEIN A-I; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GLYCOSIDES; HEPARIN; HEPARITIN SULFATE; HUMANS; LYSOSOMES; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SULFATES; SULFUR; SWINE;

EID: 84943329385     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.652545     Document Type: Article

References (67)

1. Tall, A. R. (2008) Cholesterol efflux pathways and other potential mechanisms involvedin the athero-protective effect ofhigh density lipoproteins. J. Intern. Med. 263, 256-273
2. Rader, D. J., and Alexander., E. T., Weibel, G. L., Billheimer, J., and Rothblat, G. H. (2009) The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50, S189-S194
3. Segrest, J. P., and Jones., M. K., De Loof, H., Brouillette, C. G., Venkatachalapathi, Y.V., and Anantharamaiah, G. M. (1992) The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J. Lipid Res. 33, 141-166
4. Brouillette, C. G., and Anantharamaiah., G. M., Engler, J. A., and Borhani, D. W. (2001) Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim. Biophys. Acta 1531, 4-46
5. Saito, H., Dhanasekaran, P., Nguyen, D., Holvoet, P., Lund-Katz, S., and Phillips, M. C. (2003) Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model. J. Biol. Chem. 278, 23227-23232
6. Sorci-Thomas, M. G., and Thomas, M. J. (2002) The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc. Med. 12, 121-128
7. Obici, L., Franceschini, G., Calabresi, L., Giorgetti, S., Stoppini, M., Merlini, G., and Bellotti, V. (2006) Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 13, 191-205
8. Gomaraschi, M., Obici, L., Simonelli, S., Gregorini, G., Negrinelli, A., Merlini, G., Franceschini, G., and Calabresi, L. (2011) Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations. Clin. Chim. Acta 412, 1262-1265
9. Rowczenio, D., Dogan, A., Theis, J. D., Vrana, J. A., Lachmann, H. J., Wechalekar, A. D., Gilbertson, J. A., Hunt, T., Gibbs, S. D., Sattianayagam, P. T., Pinney, J. H., Hawkins, P. N., and Gillmore, J. D. (2011) Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am. J. Pathol. 179, 1978-1987
10. Van Allen, M. W., Frohlich, J. A., and Davis, J. R. (1969) Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer. Neurology 19, 10-25
11. Nichols, W. C, Gregg, R. E., Brewer, H. B., Jr., and Benson, M. D. (1990) A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics 8, 318-323
12. Nichols, W. C, Dwulet, F. E., Liepnieks, J., and Benson, M. D. (1988) Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. Biochem. Biophys. Res. Commun. 156, 762-768
13. Adachi, E., Nakajima, H., Mizuguchi, C, Dhanasekaran, P., Kawashima, H., Nagao, K., Akaji, K., Lund-Katz, S., Phillips, M. C, and Saito, H. (2013) Dual role of an N-terminal amyloidogenic mutation in apolipoprotein A-I: destabilization of helix bundle and enhancement of fibril formation. J. Biol. Chem. 288, 2848-2856
14. Bishop, J. R., Schuksz, M., and Esko, J. D. (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030-1037
15. Gallagher, J. T. (2001) Heparan sulfate: growth control with a restricted sequence menu. J. Clin. Invest. 108, 357-361
16. Esko, J.D., and Selleck, S. B. (2002) Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71, 435-471
17. Morimoto-Tomita, M., Uchimura, K., Werb, Z., Hemmerich, S., and Rosen, S. D. (2002) Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J. Biol. Chem. 277, 49175-49185
18. Uchimura, K, Morimoto-Tomita, M., Bistrup, A, Li, J., Lyon, M., Gallagher, J., Werb, Z., and Rosen, S. D. (2006) HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem. 7, 2
19. Ai, X., and Do., A. T., Lozynska, O., Kusche-Gullberg, M., Lindahl, U., Emerson, C. P., Jr. (2003) QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J. Cell Biol. 162, 341-351
20. Viviano, B. L., Paine-Saunders, S., Gasiunas, N, Gallagher, J., and Saunders, S. (2004) Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist Noggin. J. Biol. Chem. 279, 5604-5611
21. Snow, A. D., and Kisilevsky, R. (1985) Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. A histochemical study. Lab. Invest. 53, 37-44
22. Young, I. D., and Willmer., J. P., and Kisilevsky, R. (1989) The ultrastructural localization of sulfated proteoglycans is identical in the amyloids of Alzheimer's disease and AA, AL, senile cardiac and medullary carcinomaassociated amyloidosis. Acta Neuropathol. 78, 202-209
23. Snow, A. D., Mar, H., Nochlin, D., Kimata, K., Kato, M., Suzuki, S., Hassell, J., and Wight, T.N. (1988) The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am. J. Pathol. 133, 456-463
24. Snow, A. D., Mar, H, Nochlin, D., and Sekiguchi., R. T., Kimata, K., Koike, Y., and Wight, T. N. (1990) Early accumulation of heparan sulfate in neurons and in the β-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. Am. J. Pathol. 137, 1253-1270
25. Perlmutter, L. S., Chui, H. C, Saperia, D., and Athanikar, J. (1990) Microangiopathy and the colocalization of heparan sulfate proteoglycan with amyloid in senile plaques of Alzheimer's disease. Brain Res. 508, 13-19
26. Hosono-Fukao, T., Ohtake-Niimi, S., Hoshino, H., Britschgi, M., Akatsu, H, and Hossain., M. M., Nishitsuji, K., van Kuppevelt, T. H., Kimata, K., Michikawa, M., Wyss-Coray, T., and Uchimura, K. (2012) Heparan sulfate subdomains that are degraded by Sulf accumulate in cerebral amyloid β plaques of Alzheimer's disease: evidence from mouse models and patients. Am. J. Pathol. 180, 2056-2067
27. Snow, A. D., Kisilevsky, R., Willmer, J., Prusiner, S. B., and DeArmond, S. J. (1989) Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol. 77, 337-342
28. Young, I. D., Ailles, L., Narindrasorasak, S., Tan, R., and Kisilevsky, R. (1992) Localization of the basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type II diabetes mellitus. Arch. Pathol. Lab. Med. 116, 951-954
29. Sandwall, E., O'Callaghan, P., Zhang, X., Lindahl, U., Lannfelt, L., and Li, J. P. (2010) Heparan sulfate mediates amyloid-β internalization and cytotoxicity. Glycobiology 20, 533-541
30. Nishitsuji, K., Hosono, T., Uchimura, K., and Michikawa, M. (2011) Lipoprotein lipase is a novel amyloid β (Aβ)-binding protein that promotes glycosaminoglycan-dependent cellular uptake of Aβ in astrocytes. J. Biol. Chem. 286, 6393-6401
31. Ramella, N. A., and Rimoldi., O. J., Prieto, E. D., Schinella, G. R., Sanchez, S. A., Jaureguiberry, M. S., Vela, M. E., Ferreira, S. T., and Tricerri, M. A. (2011) Human apolipoprotein A-I-derived amyloid: its association with atherosclerosis. PLoS ONE 6, e22532
32. Hossain, M. M., Hosono-Fukao, T., Tang, R., Sugaya, N, van Kuppevelt, T. H., Jenniskens, G. J., Kimata, K., Rosen, S. D., and Uchimura, K. (2010) Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. Glycobiology 20, 175-186
33. Najjam, S., and Gibbs., R. V., Gordon, M. Y., and Rider, C. C. (1997) Characterization of human recombinant interleukin 2 binding to heparin and heparan sulfate using an ELISA approach. Cytokine 9, 1013-1022
34. Morrow, J. A., and Arnold., K. S., and Weisgraber, K. H. (1999) Functional characterization of apolipoprotein E isoforms overexpressed in Escherichia coli. Protein Expr. Purif. 16, 224-230
35. Tanaka, M., Koyama, M., Dhanasekaran, P., Nguyen, D., Nickel, M., Lund-Katz, S., Saito, H., and Phillips, M. C. (2008) Influence of tertiary structure domain properties on the functionality of apolipoprotein A-I. Biochemistry 47, 2172-2180
36. Omura, R., Nagao, K., Kobayashi, N, Ueda, K., and Saito, H. (2014) Direct detection of ABCA1-dependent HDL formation based on lipidation-in-duced hydrophobicity change in apoA-I. J. Lipid Res. 55, 2423-2431
37. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63
38. Niikura, Y., Nonaka, T., and Imajoh-Ohmi, S. (2002) Monitoring of caspase-8/FLICE processing and activation upon Fas stimulation with novel antibodies directed against a cleavage site for caspase-8 and its substrate, FLICE-like inhibitory protein (FLIP). J. Biochem. 132, 53-62
39. Kreuger, J., Lindahl, U., and Jemth, P. (2003) Nitrocellulose filter binding to assess binding of glycosaminoglycans to proteins. Methods Enzymol. 363, 327-339
40. Lidholt, K., and Weinke., J. L., Kiser, C. S., Lugemwa, F. N, Bame, K. J., Cheifetz, S., Massagué, J., Lindahl, U., and Esko, J. D. (1992) A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltrans-ferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 89, 2267-2271
41. Horonchik, L., Tzaban, S., Ben-Zaken, O., Yedidia, Y., Rouvinski, A., Papy-Garcia, D., Barritault, D., Vlodavsky, I., and Taraboulos, A. (2005) Heparan sulfate is a cellular receptor for purified infectious prions. J. Biol. Chem. 280, 17062-17067
42. de Duve, C, de Barsy, T., Poole, B., Trouet, A., Tulkens, P., and Van Hoof, F. (1974) Commentary. Lysosomotropic agents. Biochem. Pharmacol. 23, 2495-2531
43. Bernas, T., and Dobrucki, J. (2002) Mitochondrial and nonmitochondrial reduction of MTT: interaction of MTT with TMRE, JC-1, and NAO mitochondrial fluorescent probes. Cytometry 47, 236-242
44. Scaduto, R. C, Jr., and Grotyohann, L. W. (1999) Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys. J. 76, 469-477
45. Kroemer, G., and Jäättelä, M. (2005) Lysosomes and autophagy in cell death control. Nat Rev. Cancer 5, 886-897
46. Gallagher, J. T., and Walker, A. (1985) Molecular distinctions between heparan sulphate and heparin. Analysis of sulphation patterns indicates that heparan sulphate and heparin are separate families of N-sulphated polysaccharides. Biochem. J. 230, 665-674
47. Fraser, J. R., Laurent, T. C, and Laurent, U. B. (1997) Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 242, 27-33
48. Robinson, J., and Gospodarowicz, D. (1984) Effect ofp-nitrophenyl-β-Dxyloside on proteoglycan synthesis and extracellular matrix formation by bovine corneal endothelial cell cultures. J. Biol. Chem. 259, 3818-3824
49. Safaiyan, F., and Kolset., S. O., Prydz, K., Gottfridsson, E., Lindahl, U., and Salmivirta, M. (1999) Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate. J. Biol. Chem. 274, 36267-36273
50. Dennissen, M. A., and Jenniskens., G. J., Pieffers, M., Versteeg, E. M., Petitou, M., Veerkamp, J. H., and van Kuppevelt, T. H. (2002) Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. J. Biol. Chem. 277, 10982-10986
51. Kisilevsky, R., and Ancsin., J. B., Szarek, W. A., and Petanceska, S. (2007) Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 14, 21-32
52. Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., and Zako, M. (1999) Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729-777
53. Guan, J., Mishra, S., Qiu, Y., Shi, J., Trudeau, K., Las, G., Liesa, M., and Shirihai., O. S., Connors, L. H., Seldin, D. C, Falk, R. H, MacRae, C. A., and Liao, R. (2014) Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO. Mol. Med. 6, 1493-1507
54. Nagamine, S., Tamba, M., Ishimine, H., Araki, K., Shiomi, K., Okada, T., Ohto, T., Kunita, S., Takahashi, S., Wismans, R. G., van Kuppevelt, T. H, Masu, M., and Keino-Masu, K. (2012) Organ-specific sulfation patterns of heparan sulfate generated by extracellular sulfatases Sulf1 and Sulf2 in mice. J. Biol. Chem. 287, 9579-9590
55. Watson, D. J., and Lander., A. D., and Selkoe, D. J. (1997) Heparin-binding properties of the amyloidogenic peptides Aβ and amylin. Dependence on aggregation state and inhibition by Congo red. J. Biol. Chem. 272, 31617-31624
56. Ancsin, J. B., and Kisilevsky, R. (1999) The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J. Biol. Chem. 274, 7172-7181
57. Cohlberg, J. A., Li, J., Uversky, V. N, and Fink, A. L. (2002) Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry 41, 1502-1511
58. Supattapone, S. (2004) Prion protein conversion in vitro. J. Mol. Med. 82, 348-356
59. Motamedi-Shad, N, Monsellier, E., Torrassa, S., Relini, A., and Chiti, F. (2009) Kinetic analysis of amyloid formation in the presence of heparan sulfate: faster unfolding and change of pathway. J. Biol. Chem. 284, 29921-29934
60. Goedert, M., Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., and Crowther, R. A. (1996) Assembly of microtubule-associated protein Tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550-553
61. McLaurin, J., Franklin, T., Zhang, X., Deng, J., and Fraser, P. E. (1999) Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur. J. Biochem. 266, 1101-1110
62. Castillo, G. M., Lukito, W., Wight, T. N, and Snow, A. D. (1999) The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation. J. Neurochem. 72, 1681-1687
63. 42 fibrillogenesis by glycosaminoglycan structure. FASEBJ. 24, 4250-4261
64. Vigushin, D. M., Gough, J., Allan, D., Alguacil, A., Penner, B., Pettigrew, N. M., Quinonez, G., Bernstein, K., and Booth., S. E., and Booth, D. R. (1994) Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26. Q. J. Med. 87, 149-154
65. Traynor, C. A., Tighe, D., O'Brien, F. J., Leavey, S. F., Dorman, A. M., Denton, M. D., Magee, C, and Conlon, P. J. (2013) Clinical and pathologic characteristics of hereditary apolipoprotein A-I amyloidosis in Ireland. Nephrology 18, 549-554
66. Groffen, A. J., and Veerkamp., J. H., Monnens, L. A., and van den Heuvel, L. P. (1999) Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Nephrol. Dial. Transplant. 14, 2119-2129
67. Rops, A. L., van der Vlag, J., Lensen, J. F., Wijnhoven, T. J., van den Heuvel, L. P., van Kuppevelt, T. H., and Berden, J. H. (2004) Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int. 65, 768-785